Pernix Therapeutics Announces the Issuance of New Orange Book Patent for Zohydro® ER With BeadTek™ CII
February 23, 2016 08:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark...
Pernix Therapeutics to Present at RBC Capital Markets 2016 Global Healthcare Conference
February 18, 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief...
Pernix Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference
December 01, 2015 16:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief...
Pernix Therapeutics to Present at Stifel 2015 Healthcare Conference
November 13, 2015 07:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President...
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
November 12, 2015 11:15 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV...
Pernix Therapeutics to Host Meetings at Upcoming Conferences
November 10, 2015 16:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and...
Pernix Therapeutics Reports Third Quarter 2015 Financial Results
November 05, 2015 06:50 ET
|
Pernix Therapeutics Holdings, Inc.
Revenue Increases 54% Year-Over-Year Company Reiterates Financial Guidance MORRISTOWN, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or “the...
Pernix Therapeutics Holdings, Inc. to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015
October 22, 2015 09:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release its 2015 third quarter...
Pernix Announces the Issuance of Zohydro ER With BeadTek Formulation Patent
September 24, 2015 09:23 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the central patent for Zohydro ER®...
Pernix Presents Data on Novel Extended Release Formulation of Hydrocodone Bitartrate at PAINWeek
September 09, 2015 07:30 ET
|
Pernix Therapeutics Holdings, Inc.
Next-Generation Tablet Formulation Resists Physical Manipulation and Extraction of Hydrocodone
In Vitro Data Supports Further Human Abuse Liability Studies
LAS VEGAS, Sept. 9, 2015 (GLOBE...